

Financial news for OREX dated on 2018-04-23: Pernix Therapeutics Reports Agreement To Participate In Investor Group Which Entered 'Stalking Horse' Asset Purchase Deal To Buy Certain Assets Of Orexigen Therapeutics

Financial news for OREX dated on 2018-04-23: UPDATE: Orexigen To Sell World-Wide Rights To Contrave/Mysimba And Certain Other Assets For \$75M In Cash; Deal Is Subject To Higher And Better Offers

Financial news for OREX dated on 2018-04-23: Orexigen Therapeutics, Inc. Enters Agreement for Sale of Company To Nalpropion Pharmaceuticals For \$75M Cash

Financial news for OREX dated on 2018-03-16: Orexigen Says Does Not Believe Will Be In Position to Submit Materials Sufficient to Satisfy Nasdaq Hearings Panel Related to Additional Deficiency

Financial news for OREX dated on 2018-03-13: 46 Biggest Movers From Yesterday

Financial news for OREX dated on 2018-03-12: Mid-Afternoon Market Update: BlueLinx Surges On Cedar Creek Acquisition; Anthera Pharmaceuticals Shares Plunge

Financial news for OREX dated on 2018-03-12: 32 Stocks Moving In Monday's Mid-Day Session

Financial news for OREX dated on 2018-03-12: Mid-Day Market Update: Dow Turns Negative; United Community Bancorp Shares Spike Higher

Financial news for OREX dated on 2018-03-12: Mid-Morning Market Update: Markets Open Higher; Lumentum To Acquire Oclaro For \$9.99/Share

Financial news for OREX dated on 2018-03-12: Orexigen Shares Down 74.3% After Co. Announced It Would File Voluntary Petition Under Chapter 11 Of Bankruptcy Code, Plans For Near-Term Sale

Financial news for OREX dated on 2018-03-12: Orexigen Therapeutics to File a Voluntary Petition under Chapter 11 of the Bankruptcy Code

Financial news for OREX dated on 2018-02-12: Nineteen77 Global Multi-Strategy Alpha Master Limited Reports 9.99% Stake In Orexigen Therapeutics

Financial news for OREX dated on 2018-01-19: Orexigen Therapeutics Expects Annual Savings Associated With Reduction Of Sales Force Of ~\$30M

Financial news for OREX dated on 2018-01-05: Orexigen Struggles As Contrave Commercialization Costs Rise

Financial news for OREX dated on 2017-12-01: Orexigen 8-K Shows ~2.135M Share Common Stock Offering Related To Exchange Offer For 2.75% Convertible Exchange Senior Notes Due 2020

Financial news for OREX dated on 2017-11-13: Orexigen Therapeutics Reports Q3 EPS \$(1.35) vs \$(2.13) Est., Sales \$18.903M vs \$24.2M Est.

Financial news for OREX dated on 2017-11-13: Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA for Contrave in Latin America

Financial news for OREX dated on 2017-11-13: Earnings Scheduled For November 13, 2017

Financial news for OREX dated on 2017-10-13: Orexigen Release Confirms Favorable Decision From US District Court In Patent Litigation, Confirming Exclusivity For Contrave Through 2030

Financial news for OREX dated on 2017-10-13: Watching Shares Of Orexigen Therapeutics, Hearing Co. Received Positive Patent News

Financial news for OREX dated on 2017-08-08: Orexigen Therapeutics Reports Q2 EPS \$(2) vs \$(1.73) In Same Qtr. Last Year, Sales \$23.4M vs \$19.14M Est.

Financial news for OREX dated on 2017-08-07: Orexigen Therapeutics Announces Distribution Agreement with CHephlapharm for Mysimba

Financial news for OREX dated on 2017-08-03: Telemetry Investments Reports 7.6% Stake In Orexigen Therapeutics

Financial news for OREX dated on 2017-07-26: Orexigen Therapeutics Reports Expansion Of Distributor Deal With Biologix FZCO For Contrave To Egypt

Financial news for OREX dated on 2017-07-20: 15 Biggest Mid-Day Gainers For Thursday

Financial news for OREX dated on 2017-05-09: Orexigen Therapeutics Reports Q1 EPS \$(4.67) vs \$(1.54) In Same Qtr. Last Year, Sales \$19.1M vs \$20M Est.

Financial news for OREX dated on 2017-05-02: Exclusive: Orexigen Therapeutics Execs Talk Contrave And The Stock's Roller-Coaster Ride

Financial news for OREX dated on 2017-05-02: UPDATE: Orexigen CFO Tells Benzinga Acquisition Of Contrave Caused Potential Dilution, Uncertainty For Investors; Stock's Current Rebound Shows Inflection In Contrave Prescription Trajectory

Financial news for OREX dated on 2017-05-02: Orexigen CEO Tells Benzinga In Interview Total Market For Co.'s Contrave Is 'Massive,' Can Grow Beyond Current 8% Market Share

Financial news for OREX dated on 2017-05-02: Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Navamedic ASA for Mysimba in Denmark, Finland, Iceland, Norway and Sweden

Financial news for OREX dated on 2017-04-27: Orexigen Spikes to High of \$3.81 on Volume

Financial news for OREX dated on 2017-04-11: 20 Stocks Moving In Tuesday's Pre-Market Session

Financial news for OREX dated on 2017-04-03: 12 Biggest Mid-Day Losers For Monday

Financial news for OREX dated on 2017-03-28: Orexigen Therapeutics Reports Q4 EPS \$(1.69) vs \$(1.18) Est., Sales \$13.883M vs \$13.95M Est.

Financial news for OREX dated on 2017-03-28: Earnings Scheduled For March 28, 2017

Financial news for OREX dated on 2017-03-27: Orexigen Therapeutics Announces Agreement With Bruno Farmaceutici For Commercialization, Distribution Of Mysimba In Italy

Financial news for OREX dated on 2017-03-02: The Unlikely Story Of How Amicus Therapeutics Came To Be

Financial news for OREX dated on 2017-02-17: UPDATE: Orexigen Sees Q4 Contrave ~\$11.5M-\$12M; Sees FY16 Contrave \$46.6M-\$47.1M vs \$62M Est.

Financial news for OREX dated on 2017-02-17: 8-K from Orexigen Therapeutics Shows Q4 Sales ~\$13.4M-\$13.9M vs \$12.54M Est.; Sees FY16 Sales \$33.3M-\$33.8M vs \$34M Est.

Financial news for OREX dated on 2017-02-09: Orexigen Pops to High of \$5.15 on Volume; Co Released Slide Presentation Earlier

Financial news for OREX dated on 2017-02-03: Orexigen Spikes to High of \$4.22 on Volume

Financial news for OREX dated on 2017-01-25: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for OREX dated on 2017-01-25: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for OREX dated on 2017-01-25: Orexigen Therapeutics Announces Spanish Launch of Mysimba

Financial news for OREX dated on 2017-01-20: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for OREX dated on 2017-01-13: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for OREX dated on 2017-01-13: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for OREX dated on 2017-01-12: Option Alert: Orexigen Feb 4.0 Calls Sweep: 2315 @ ASK \$0.40: 3020 traded vs 55 OI: Earnings 2/23 After Close (est) \$3.18 Ref

Financial news for OREX dated on 2017-01-09: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for OREX dated on 2017-01-09: Orexigen Releases Presentation for #JPM17

Financial news for OREX dated on 2017-01-06: 15 Biggest Mid-Day Losers For Friday

Financial news for OREX dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market

Session

Financial news for OREX dated on 2017-01-05: Orexigen Therapeutics Pops to High of \$3.53 on Volume

Financial news for OREX dated on 2017-01-04: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for OREX dated on 2017-01-04: Traders Attributing Strength In Orexigen To A New Ad Campaign That Will Launch This Week Called 'Brains Behind Weight Loss'

Financial news for OREX dated on 2016-12-23: 15 Stocks With The Highest Forecast Sales Growth

Financial news for OREX dated on 2016-12-19: Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Biologix FZCO for Contrave Fro 10 Countries In Middle East

Financial news for OREX dated on 2016-12-07: Worst Performing Industries For December 7, 2016

Financial news for OREX dated on 2016-11-08: Orexigen Therapeutics Reports Commercialization and Distributorship Agreement with Valeant for Contrave in Australia and New Zealand

Financial news for OREX dated on 2016-11-03: Orexigen Therapeutics Reports Q3 EPS \$1.12 Does Not Compare To Est. \$(2.24), Rev. \$7M vs. Est. \$8.1M

Financial news for OREX dated on 2016-08-30: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for OREX dated on 2016-08-30: Mid-Morning Market Update: Markets Mostly Flat; G-III Apparel Misses Q2 Expectations

Financial news for OREX dated on 2016-08-30: Orexigen Shares Up 14% After Commercialization, Distribution Deal With Valeant Canada

Financial news for OREX dated on 2016-08-30: Orexigen Therapeutics Announces Distribution Agreement With Valeant Canada for Contrave

Financial news for OREX dated on 2016-08-04: Orexigen Therapeutics Reports Q2 EPS \$(1.73) vs. Est. \$(1.47), Rev. \$7.8M vs. Est. \$6.8M

Financial news for OREX dated on 2016-08-01: Orexigen Reports Commercialization, Distributorship Deal with Laboratorios Farmaceuticos Rovi in Spain

Financial news for OREX dated on 2016-08-01: Orexigen Therapeutics Reacquired All Commercial Rights to Cotrave from Takeda Pharmaceutical

Financial news for OREX dated on 2016-07-26: Stocks Hitting 52-Week Lows

Financial news for OREX dated on 2016-07-19: Mark N. Lampert Reports 9.99% Passive Stake in Orexigen Therapeutics in 13G

Financial news for OREX dated on 2016-07-08: Orexigen Reports 1-For-10 Reverse Stock Split

Financial news for OREX dated on 2016-06-08: Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO

Financial news for OREX dated on 2016-06-08: Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave Patent Litigation, Majority Of Orexigen's Claim Construction Adopted In Ruling

Financial news for OREX dated on 2016-05-27: Orexigen Therapeutics Founder and Former Chairman Dr. Eckard Weber Resigns From Board Of Directors

Financial news for OREX dated on 2016-05-04: Orexigen Reports Q1 EPS \$(0.15) vs \$(0.17) Est., Sales \$5M vs \$8.3M Est.

Financial news for OREX dated on 2016-05-03: Orexigen Names Brian Longstreet as Senior VP of Global Market Access and Development

Financial news for OREX dated on 2016-05-02: Orexigen Announces South Korean Approval of Contrave, Has Shipped Initial Order Of Contrave Tablets To Kwang Dong Pharmaceutical Company For \$5.9M

Financial news for OREX dated on 2016-04-21: Stocks Hitting 52-Week Lows

Financial news for OREX dated on 2016-03-16: UPDATE: JMP Securities Sees Increasing Risk To Orexigen Therapeutics LT Success, Says NT Growth Dampened By Commercial

Strategy Changes, Disappointed With Co's Departure From Contrave

Financial news for OREX dated on 2016-03-16: JMP Securities Downgrades Orexigen Therapeutics to Market Perform

Financial news for OREX dated on 2016-03-15: Orexigen Up, Then Steeply Down Following Contrave U.S. Rights Agreement

Financial news for OREX dated on 2016-03-15: From Conf Call: Orexigen CEO Says Expect to Announce Several New Partnerships in 2016

Financial news for OREX dated on 2016-03-15: Shares of Orexigen Resume Trade, Up ~6%

Financial news for OREX dated on 2016-03-15: Orexigen Announces Will Host Conference Call at 8:30 a.m. EDT to Discuss Purchase of US Rights to Contrave, Deal with Valeant

Financial news for OREX dated on 2016-03-15: Shares of Orexigen to Resume Trade at 7:30 a.m. EDT

Financial news for OREX dated on 2016-03-15: Orexigen Reported Commercialization, Distributorship Deal with Valeant for Mysimba for 18 Central, Eastern European Countries, Turkey

Financial news for OREX dated on 2016-03-15: Orexigen Shares Halted to Announce Deal with Takeda

Financial news for OREX dated on 2016-03-15: Orexigen Therapeutics Enters Agreement With Takeda Pharma For US Rights To Contrave

Financial news for OREX dated on 2016-03-01: Orexigen Halted on Circuit Breaker @ \$0.85

Financial news for OREX dated on 2016-02-29: Vivus And Orexigen Have Too Many Problems For Investors, RBC's Simeonidis Claims

Financial news for OREX dated on 2016-02-29: Benzinga's Top Downgrades

Financial news for OREX dated on 2016-02-29: JP Morgan Downgrades Orexigen Therapeutics to Neutral

Financial news for OREX dated on 2016-02-29: RBC Capital Downgrades Orexigen Therapeutics to Sector Perform, Lowers PT to \$1.00

Financial news for OREX dated on 2016-02-26: Orexigen Therapeutics Q4 EPS (\$0.12) vs (\$0.08) est, Revenue \$4.9M vs \$14.1M est

Financial news for OREX dated on 2016-02-23: Leerink Downgrades Orexigen, Cuts Target From \$4.50 To \$2

Financial news for OREX dated on 2016-02-23: Leerink Swann Downgrades Orexigen Therapeutics to Market Perform

Financial news for OREX dated on 2016-02-08: 8-K Filing Orexigen Agrees To Raises President/CEO Narachi's & EVP Klassen's Base Salary By 3% in 2016 To \$679,639 And \$402,347 Respectively

Financial news for OREX dated on 2016-01-11: Orexigen Reports FY16 Financial Outlook, Focus Is Managing To Profitability By Year End 2018

Financial news for OREX dated on 2015-12-29: 10 Biotechs Short Sellers Are Betting Against

Financial news for OREX dated on 2015-12-16: WallachBeth Downgrades Orexigen Therapeutics to Hold

Financial news for OREX dated on 2015-12-11: Benzinga's Top Initiations

Financial news for OREX dated on 2015-12-11: Bank of America Initiates Coverage on Orexigen Therapeutics at Underperform, Announces \$2.00 PT

Financial news for OREX dated on 2015-12-04: Wells Fargo Downgrades Orexigen Therapeutics to Market Perform

Financial news for OREX dated on 2015-11-13: Baupost Shows New ~821K Share Stake in Orexigen

Financial news for OREX dated on 2015-11-05: Orexigen Therapeutics Reports Q3 EPS \$(0.09) vs \$(0.16) Est., Sales \$10M vs \$12.17M Est.

Financial news for OREX dated on 2015-10-16: Mid-Morning Market Update: Markets Edge Higher; General Electric Profit Tops Expectations

Financial news for OREX dated on 2015-10-16: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2015-10-12: Morning Market Gainers

Financial news for OREX dated on 2015-10-12: Orexigen Therapeutics +6% Premarket; Baupost Group Reported 17.17% Passive Stake in Orexigen on Friday

Financial news for OREX dated on 2015-10-12: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2015-10-09: After-Hours Moves Led By Orexigen Therapeutics, EMC, Clean Energy Fuels And Cadiz

Financial news for OREX dated on 2015-10-09: 13G Filing: The Baupost Group Reports 17.17% Stake In Orexigen Therapeutics

Financial news for OREX dated on 2015-10-01: Orexigen Reports Submission of Contrave New Drug Application in South Korea

Financial news for OREX dated on 2015-09-23: Orexigen Announces Received Payment of \$22M from Us, Korean Partners Related to Milestone Payments

Financial news for OREX dated on 2015-09-16: Mid-Morning Market Update: Markets Mixed; FedEx Earnings Miss Estimates

Financial news for OREX dated on 2015-09-10: Mid-Morning Market Update: Markets Mostly Flat; Krispy Kreme Misses Q2 Estimates

Financial news for OREX dated on 2015-09-10: Morning Market Gainers

Financial news for OREX dated on 2015-09-10: Orexigen Raises \$60M Following Common Stock Sale To Baupost

Financial news for OREX dated on 2015-08-20: Option Alert: Orexigen Aug \$5 Call Sweep; 3611 Contracts above Ask @\$0.21; Now \$3.12

Financial news for OREX dated on 2015-08-06: Orexigen Shares Moving Higher; May be Attributed to Piper PT Raise

Financial news for OREX dated on 2015-08-06: Morning Market Gainers

Financial news for OREX dated on 2015-08-06: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2015-08-06: Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Company

Financial news for OREX dated on 2015-07-29: Orexigen Shares Falling on Volume

Financial news for OREX dated on 2015-07-24: Option Alert: Orexigen Aug \$3.5 Call Sweep; 1000 Contracts @Ask @\$0.80; Now \$4.19

Financial news for OREX dated on 2015-07-21: Orexigen Therapeutics Spikes Lower

Financial news for OREX dated on 2015-07-08: Option Alert: Orexigen Aug \$5 Call; 3965 Contracts vs 95 OI; Now \$4.61

Financial news for OREX dated on 2015-06-09: Orexigen Therapeutics Shares Spike Lower

Financial news for OREX dated on 2015-06-05: Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave Ignite Study at the Annual Meeting of the American Diabetes Association

Financial news for OREX dated on 2015-05-29: Option Alert: Orexigen Jul \$5.5 Call; 1035 Contract Trade at Ask @\$0.20

Financial news for OREX dated on 2015-05-13: Morning Market Losers

Financial news for OREX dated on 2015-05-13: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2015-05-12: Tuesday's After-Hours Movers: Vertex Pharmaceuticals, Orexigen Therapeutics And More

Financial news for OREX dated on 2015-05-12: Orexigen Provides Statement on Termination of Light Study; Updates on Contrave Collaboration with Takeda Pharmaceuticals

Financial news for OREX dated on 2015-05-12: Heart Benefit For Orexigen Drug Nearly

Vanishes With New Data -Forbes

Financial news for OREX dated on 2015-05-12: Takeda Pharmaceuticals, Orexigen Terminate Cardiovascular Outcomes Study of Contrave

Financial news for OREX dated on 2015-05-12: Takeda Pharmaceuticals and Orexigen Therapeutics Terminate the Cardiovascular Outcomes Study of the Obesity Drug Contrave (naltrexone HCl and bupropion HCl)

Financial news for OREX dated on 2015-05-08: Orexigen Therapeutics Reports Inline Q1 Loss \$0.14, Sales \$4.36M

Financial news for OREX dated on 2015-04-22: Orexigen Reports Receipt of Paragraph IV Certification Notice

Financial news for OREX dated on 2015-04-13: 7 Trends Drug Investors Should Know

Financial news for OREX dated on 2015-04-07: Research & Clinical Trials for Prevention of Neurodegeneration Search for Viable Therapeutic Approach for the Treatment of Severe Alzheimer's

Financial news for OREX dated on 2015-03-30: Orexigen Therapeutics Names Tom Cannell Chief Commercial Officer

Financial news for OREX dated on 2015-03-30: Leerink: Europe Deal Coming For Orexigen Therapeutics

Financial news for OREX dated on 2015-03-27: Morning Market Gainers

Financial news for OREX dated on 2015-03-27: Orexigen Shares Continue to Rebound Following ~12% Sell Off Over Last Friday to Wednesday Sessions: Stock Was Up Nearly 5% on Thurs, Up ~8% Premarket

Financial news for OREX dated on 2015-03-27: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2015-03-27: Orexigen Therapeutics Shares Rise 15% Premarket Following Thursday's EC Approval of Mysimba

Financial news for OREX dated on 2015-03-26: Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers

Financial news for OREX dated on 2015-03-26: Orexigen Shares Spike Higher After-Hours on CNBC Mention

Financial news for OREX dated on 2015-03-26: Orexigen's Mysimba Approved by EC Treatment of Obesity

Financial news for OREX dated on 2015-03-26: UPDATE: Orexigen's Mysimba Approved In Europe For Obesity Treatment Confirmed

Financial news for OREX dated on 2015-03-26: Document Appears to Show Approval of Orexigen's Mysimba in Europe

Financial news for OREX dated on 2015-03-09: Morning Market Losers

Financial news for OREX dated on 2015-03-09: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2015-03-06: Analyst: FDA Won't Pull Permit On Orexigen Therapeutics

Financial news for OREX dated on 2015-03-06: RBC Says Buy the Dip in Shares of Orexigen; Cites Eventual EU Approval of Contrave, Continued Strong US Launch by Takeda Salesforce

Financial news for OREX dated on 2015-03-06: Morning Market Losers

Financial news for OREX dated on 2015-03-06: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2015-03-05: Orexigen Shares Sell Off After-Hours on Reports Company Could Face Fines, Penalties Over Early Release of Data

Financial news for OREX dated on 2015-03-05: Takeda Disagrees With Orexigen Over Data Disclosure -Forbes

Financial news for OREX dated on 2015-03-04: Wednesday's Mid-Day Movers: PhotoMedex, Career Education And More

Financial news for OREX dated on 2015-03-04: Leerink Comments On Orexigen Therapeutics, Says Current Projections Could Prove To Be 'Conservative'

Financial news for OREX dated on 2015-03-04: Orexigen Therapeutics Shares Rise 6% Premarket; Leerink Raises PT from \$8 to \$11 With Outperform Rating

Financial news for OREX dated on 2015-03-03: Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study

Financial news for OREX dated on 2015-03-03: FDA Will Force Orexigen to Do Second Safety Study Because Of Contrave Disclosures -Forbes

Financial news for OREX dated on 2015-03-03: Adam Feuerstein @adamfeuerstein Oops! Tweet: --> \$OREX Released Interim Data Without Approval Of Trial Leaders onforb.es/1CqY7ln via @cardiobrief

Financial news for OREX dated on 2015-03-03: Option Alert: Orexigen Apr \$8 Call; 1000 Contract Trade at Ask @\$1.00

Financial news for OREX dated on 2015-03-03: Hearing Piper Jaffray Raises Target on Orexigen Therapeutics from \$16 to \$26, Maintains Overweight

Financial news for OREX dated on 2015-03-03: Orexigen Therapeutics Shares +18, May be Attributed to 8-K Filing Regarding Patent

Financial news for OREX dated on 2015-02-25: UPDATE: Orexigen Therapeutics Shares Drop After Q4 Results

Financial news for OREX dated on 2015-02-25: Earnings Scheduled For February 25, 2015

Financial news for OREX dated on 2015-01-14: 5 Obesity Stocks Investors Are Watching

Financial news for OREX dated on 2015-01-13: Orexigen CEO Being Interviewed on CNBC

Financial news for OREX dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for OREX dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for OREX dated on 2014-12-19: Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

Financial news for OREX dated on 2014-12-19: Friday's Big Gainers With High Short Interest

Financial news for OREX dated on 2014-12-19: Orexigen Reports Positive CHMP Opinion for Mysimba

Financial news for OREX dated on 2014-12-08: How To Profit From The Obesity Epidemic

Financial news for OREX dated on 2014-12-08: These 4 Biotech Stocks Have Been On Fire

Financial news for OREX dated on 2014-11-21: Orexigen Announces Allowance Of New U.S. Patent For Contrave

Financial news for OREX dated on 2014-11-17: 2 Skyrocketing Biotech Stocks In A Stalling Market

Financial news for OREX dated on 2014-11-13: What's Driving Orexigen Therapeutics Higher?

Financial news for OREX dated on 2014-11-13: Orexigen Therapeutics Director Bock Buys 27,052 Shares @\$5.57/Share -Form 4

Financial news for OREX dated on 2014-11-10: Mid-Afternoon Market Update: Sothebys Climbs On Upbeat Revenue; GoPro Shares Dip

Financial news for OREX dated on 2014-11-10: Orexigen Therapeutics continues it's move higher on 3x daily average volume. Shares are up 33.35 percent; near, HOD of \$5.25 per share.

Financial news for OREX dated on 2014-11-10: Mid-Day Market Update: Gogo Shares Slide On Wider Loss; Achillion Pharmaceuticals Shares Jump

Financial news for OREX dated on 2014-11-10: Mid-Morning Market Update: Markets Edge Higher; Dean Foods Posts Narrower-Than-Expected Loss

Financial news for OREX dated on 2014-11-10: Morning Market Movers

Financial news for OREX dated on 2014-11-10: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2014-11-10: Orexigen Therapeutics, Inc. Reports Q3 EPS of \$0.09; Revenue of \$30.86M, Up 3.5% YOY

Financial news for OREX dated on 2014-10-31: Orexigen Announces Contrave Data Presentations At the ObesityWeek Meeting in Boston

Financial news for OREX dated on 2014-10-30: 3 Pharma Companies Fighting Obesity

Financial news for OREX dated on 2014-10-20: Takeda and Orexigen Announce Availability of CONTRAVE

Financial news for OREX dated on 2014-10-15: Milestone Payments Earned by Orexigen Total \$100 Million as Contrave is Shipped to Wholesalers in Preparation for Commercial Launch

Financial news for OREX dated on 2014-10-07: Stocks Hitting 52-Week Lows

Financial news for OREX dated on 2014-09-15: Orexigen Therapeutics CEO Narachi Buys 50,000 Shares @\$4.78/Share -Form 4

Financial news for OREX dated on 2014-09-11: FDA Panel Says Novo Nordisk's Liraglutide is Safe, Effective for Chronically Obese Patients

Financial news for OREX dated on 2014-09-11: Takeda And Orexigen Announce FDA Approval of Contrave Extended-release Tablets For Chronic Weight Management

Financial news for OREX dated on 2014-09-10: Orexigen Therapeutics to Host Conference Call Thursday September 11, 2014 at 8:30 AM ET, Shares Currently Halted

Financial news for OREX dated on 2014-09-10: Option Alert: Orexigen Shares Move Higher; Activity in Sep \$6 Call; Currently \$6.03

Financial news for OREX dated on 2014-09-08: 8-K from Orexigen Shows Service Deal with Takeda

Financial news for OREX dated on 2014-08-07: Orexigen Reports Q2 EPS Loss \$0.21, Revenues of \$857K

Financial news for OREX dated on 2014-07-30: Adam Feuerstein Tweet: '\$OREX - CHMP has further questions re: Contrave. Co. believes they are addressable, submit response Sept'

Financial news for OREX dated on 2014-07-30: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2014-07-21: Option Alert: Orexigen Sep \$5/\$7 Call Spread; 10,000 Spread Trade; Currently \$5.23

Financial news for OREX dated on 2014-06-17: Events Scheduled for Week of Jun. 16th to Jun. 20th

Financial news for OREX dated on 2014-06-13: Orexigen Shares Move Lower; 2,000 Contract Trade in Oct \$6 Put

Financial news for OREX dated on 2014-06-11: Mid-Afternoon Market Update: ULTA Salon Remains Steady After Strong Results; Orexigen Still Down 15%

Financial news for OREX dated on 2014-06-11: Mid-Day Market Update: ULTA Salon Rises After Strong Results; Orexigen Shares Slide

Financial news for OREX dated on 2014-06-11: Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

Financial news for OREX dated on 2014-06-11: Mid-Morning Market Update: Markets Drop; H&R Block Posts Higher Profit

Financial news for OREX dated on 2014-06-11: Morning Market Losers

Financial news for OREX dated on 2014-06-11: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2014-06-11: US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

Financial news for OREX dated on 2014-06-11: UPDATE: Orexigen Shares Fall 11% Premarket Following Announcement of FDA Extension of Review of Orexigen NDA for NB32

Financial news for OREX dated on 2014-06-11: UPDATE: FDA Extends Review of Orexigen NDA for NB32; Sets New PDUFA Date of September 11, 2014

Financial news for OREX dated on 2014-06-11: Orexigen Receives Three Month Extension of FDA NB32 Review

Financial news for OREX dated on 2014-05-16: Option Alert: Orexigen Therapeutics Jun \$5 Put; 1,999 Contracts Traded vs 1,016 OI; Currently \$5.28

Financial news for OREX dated on 2014-05-08: Orexigen Therapeutics, Inc. Reports Q1 EPS of \$(0.23) vs \$(0.20) Est; Revenue of \$857.0K vs \$940.0K Est

Financial news for OREX dated on 2014-03-12: Orexigen Therapeutics, Inc. Reports Q4 EPS of \$(0.21) vs \$(0.19) Est; Revenue of \$857.0K vs \$900.0K Est

Financial news for OREX dated on 2014-03-12: Earnings Scheduled For March 12, 2014

Financial news for OREX dated on 2014-01-24: Option Alert: Orexigen Therapeutics March \$5 Call; 10,358 Contracts Traded vs 0 Open Interest; Currently \$6.75

Financial news for OREX dated on 2014-01-08: Option Alert: April \$6 Call; 1,800 Contract Trade at Bid @\$0.80; Currently \$5.92

Financial news for OREX dated on 2014-01-07: Orexigen Reports June 10th, 2014 PDUFA Action Date for Contrave

Financial news for OREX dated on 2013-12-11: Orexigen Resubmits Contrave NDA to FDA

Financial news for OREX dated on 2013-12-06: Orexigen Therapeutics Announces Closing of \$115M Convertible Senior Notes Offering, Says Initially Convertible at \$8.19/Share

Financial news for OREX dated on 2013-12-02: Benzinga's Top #PreMarket Losers

Financial news for OREX dated on 2013-11-26: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2013-11-25: Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

Financial news for OREX dated on 2013-11-25: Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive Shares Spike Higher

Financial news for OREX dated on 2013-11-25: Mid-Morning Market Update: Markets Edge Higher; Wal-Mart Names New CEO

Financial news for OREX dated on 2013-11-25: Benzinga's Top #PreMarket Gainers

Financial news for OREX dated on 2013-11-25: Orexigen Announces Successful Interim Analysis of Contrave Light Study, Will Resubmit Contrave NDA to FDA

Financial news for OREX dated on 2013-11-11: Orexigen, Takeda Report Multiple Contrave Data Presentations at ObesityWeek

Financial news for OREX dated on 2013-11-06: Orexigen Reports Deal with Sanofi to Manufacture Contrave Outside of US

Financial news for OREX dated on 2013-10-03: Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

Financial news for OREX dated on 2013-10-03: Benzinga's Top Initiations

Financial news for OREX dated on 2013-10-03: Cowen & Company Initiates Coverage on Orexigen Therapeutics, Inc. at Outperform, Announces \$10.00 PT

Financial news for OREX dated on 2013-10-03: Orexigen Submits Contrave Marketing Authorization Application to EMA

Financial news for OREX dated on 2013-08-27: Mid-Afternoon Market Update: DSW Rises as the NASDAQ Gets Crushed

Financial news for OREX dated on 2013-08-27: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2013-06-21: Bank of America Reiterates Buy Rating on Orexigen Therapeutics Following Investor Meeting

Financial news for OREX dated on 2013-06-19: Senators Carper, Murkowski, Representatives Cassidy, Kind Introduce Bill to Help Reduce Obesity

Financial news for OREX dated on 2013-06-19: Hearing Chatter of Lawmakers Introducing Bill to Require Medicare to Cover Weight-Loss Drugs

Financial news for OREX dated on 2013-05-08: Orexigen Therapeutics, Inc. Reports Q1 EPS of \$(0.21) vs \$(0.34) Est; Revenue of \$857.0K vs \$890.0K Est

Financial news for OREX dated on 2013-03-13: Orexigen Therapeutics, Inc. Reports Q4 EPS of \$(0.41) vs \$(0.44) Est; Revenue of \$857.0K vs \$910.0K Est

Financial news for OREX dated on 2013-03-13: US Stock Futures Down Ahead Of Retail Sales Data

Financial news for OREX dated on 2013-03-13: Earnings Scheduled For March 13, 2013

Financial news for OREX dated on 2013-01-24: Pharmas Look to Fatten Up With Obesity Drugs

Financial news for OREX dated on 2013-01-18: Trading The News

Financial news for OREX dated on 2013-01-07: Orexigen Reports Progress on Resubmission of Contrave NDA, Sees Potential Approval in Early 2014

Financial news for OREX dated on 2013-01-04: UPDATE: Piper Jaffray Initiates Orexigen at Overweight on Valuation, Outlook

Financial news for OREX dated on 2013-01-04: Piper Jaffray Initiates Coverage on Orexigen Therapeutics, Inc. at Overweight, Announces \$10.00 PT

Financial news for OREX dated on 2012-12-18: Orexigen Concludes Light Study Patient Screening, to Randomize ~9,000 Patients, Sees Resubmission in Q4

Financial news for OREX dated on 2012-11-07: Orexigen Therapeutics Reports Q3 EPS \$-0.44 vs \$-0.30 Est

Financial news for OREX dated on 2012-11-07: VIVUS Shares Hit Hard After Earnings

Financial news for OREX dated on 2012-10-24: Orexigen Therapeutics Announces Proposed Public Offering of Common Stock

Financial news for OREX dated on 2012-10-23: Jefferies & Company Maintains Orexigen Therapeutics at Hold, Raises PT from \$5 to \$6

Financial news for OREX dated on 2012-10-22: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-10-22: Orexigen Therapeutics Receives Positive Dispute Response from FDA for Contrave

Financial news for OREX dated on 2012-09-21: Benzinga's Top Pre-Market Losers

Financial news for OREX dated on 2012-09-17: Benzinga's Top Pre-Market Losers

Financial news for OREX dated on 2012-09-17: US Stock Futures Down; Crude Oil Drops

Financial news for OREX dated on 2012-09-17: Stocks To Watch For September 17, 2012

Financial news for OREX dated on 2012-09-06: UPDATE: Orexigen Spikes to Highs Following Credit Suisse Outperform Rating

Financial news for OREX dated on 2012-09-06: Orexigen Therapeutics Rises 10% Pre-Market on Credit Suisse Initiation at Outperform

Financial news for OREX dated on 2012-09-06: Benzinga's Top Initiations

Financial news for OREX dated on 2012-09-06: Credit Suisse Initiates Coverage on Orexigen Therapeutics at Outperform

Financial news for OREX dated on 2012-09-05: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-09-05: Orexigen Therapeutics Announces Continued Rapid Enrollment into the Light Study

Financial news for OREX dated on 2012-07-18: Bank of America Maintains Orexigen Therapeutics at Buy, Raises PO from \$9 to \$10

Financial news for OREX dated on 2012-07-18: JP Morgan Maintains Orexigen Therapeutics at Overweight, Raises PT from \$10 to \$12

Financial news for OREX dated on 2012-07-17: Arena Pharmaceuticals Spiking Lower on Vivus Qnexa Approval, Orexigen Spiking Higher

Financial news for OREX dated on 2012-07-17: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-07-16: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-07-16: Leerink Swann Resumes Coverage on Orexigen Therapeutics at Outperform

Financial news for OREX dated on 2012-07-13: Orexigen Therapeutics Hits \$7/Share

Financial news for OREX dated on 2012-07-12: UPDATE: Bank of America Raises PT on Orexigen Therapeutics from \$7 to \$9.

Financial news for OREX dated on 2012-07-12: Bank of America Maintains Orexigen Therapeutics at Buy, Raises PO from \$7 to \$9

Financial news for OREX dated on 2012-07-11: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-07-11: Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected

Financial news for OREX dated on 2012-07-05: These Are Four of the Hottest Biotechs in the Market Right Now

Financial news for OREX dated on 2012-06-29: Orexigen Therapeutics Falls 6% on Profit Taking

Financial news for OREX dated on 2012-06-28: Shuffle Master, Orexigen Therapeutics Rise Following Ratings Activity

Financial news for OREX dated on 2012-06-28: Orexigen Therapeutics Rallying After Arena Pharmaceuticals' FDA Approval

Financial news for OREX dated on 2012-06-28: JP Morgan Upgrades Orexigen Therapeutics to Overweight

Financial news for OREX dated on 2012-06-28: Orexigen Therapeutics Rises 20%

Financial news for OREX dated on 2012-06-28: Orexigen Therapeutics Rises 11% Pre-Market on JP Morgan Upgrade

Financial news for OREX dated on 2012-06-28: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-06-28: Financial Breakfast: Morning News Summary for June 28, 2012

Financial news for OREX dated on 2012-06-28: UPDATE: JP Morgan Upgrades Orexigen Therapeutics to Overweight Post Belviq FDA Approval

Financial news for OREX dated on 2012-06-28: JP Morgan Upgrades Orexigen Therapeutics from Neutral to Overweight, Maintains PT at \$10

Financial news for OREX dated on 2012-06-27: FDA Approves Arena's Lorcaserin

Financial news for OREX dated on 2012-06-27: Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)

Financial news for OREX dated on 2012-06-27: Orexigen Therapeutics Hits 52-Week Highs on Arena Approval

Financial news for OREX dated on 2012-06-27: Orexigen Therapeutics Crosses \$5/Share on FDA Approval

Financial news for OREX dated on 2012-06-27: Vivus, Orexigen Spike Higher on Arena Approval

Financial news for OREX dated on 2012-06-06: A Peek Into The Market Before The Trading Starts

Financial news for OREX dated on 2012-06-06: The Light Study, a Long-Term Research Study of Investigational Weight Loss Drug Contrave(r), Begins Enrolling Patients Nationwide

Financial news for OREX dated on 2012-06-06: Orexigen Therapeutics and Sharecare(r) Announce Partnership for WeightMate

Financial news for OREX dated on 2012-05-31: Vivus' Qnexa Is Not Guaranteed Approval. Remember Provenge?

Financial news for OREX dated on 2012-05-25: 4 Smaller Alternatives to Big Pharma Obesity Treatments

Financial news for OREX dated on 2012-05-14: Orexigen Therapeutics To Be Added to the NASDAQ Biotechnology Index

Financial news for OREX dated on 2012-05-14: Orexigen Therapeutics Trading 4.8% Higher on Heavy Volume; Currently at \$4.18

Financial news for OREX dated on 2012-05-11: Hot Stocks to Keep on Your Radar Screen Next week

Financial news for OREX dated on 2012-05-11: Orexigen Therapeutics Trading 22.3% Higher on Heavy Volume; Currently at \$4.1

Financial news for OREX dated on 2012-05-11: Orexigen Therapeutics Sitting At Session Highs

Financial news for OREX dated on 2012-05-11: Arena, Vivus, Orexigen are All Takeover Targets -Optionmonster

Financial news for OREX dated on 2012-05-10: Vivus, Orexigen Spiking Higher After-Hours Following Positive FDA Panel Vote on Arena Diet Drug

Financial news for OREX dated on 2012-05-10: Orexigen Rises After-Hours on Positive FDA Panel Vote for Arena

Financial news for OREX dated on 2012-04-12: Orexigen Therapeutics Spiking Higher on Heavy Volume; Currently at \$4.07

Financial news for OREX dated on 2012-04-11: Bank of America: Key Takeaways from Orexigen Therapeutics' Management Meetings

Financial news for OREX dated on 2012-03-30: Jefferies & Company Maintains Orexigen Therapeutics at Hold, Raises PT from \$3 to \$5

Financial news for OREX dated on 2012-03-30: FDA Spokesperson Says Unlikely That Discussion Over Past Couple of Days Will Impact Any Existing Applications -Adam F. Tweet

Financial news for OREX dated on 2012-03-29: UPDATE: FDA Panel Currently Going On

Financial news for OREX dated on 2012-03-29: Orexigen Therapeutics Spiking Higher on Heavy Volume; Currently at \$4.68

Financial news for OREX dated on 2012-03-16: Orexigen Therapeutics Trading 6.4% Higher on Heavy Volume; Currently at \$4.96

Financial news for OREX dated on 2012-03-12: Orexigen Therapeutics Rises 24% on Bank of America Upgrade

Financial news for OREX dated on 2012-03-12: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-03-12: Financial Breakfast: Morning News Summary for March 12, 2012

Financial news for OREX dated on 2012-03-12: Benzinga's Top Upgrades

Financial news for OREX dated on 2012-03-12: UPDATE: Bank of America Upgrades Orexigen Therapeutics to Buy

Financial news for OREX dated on 2012-03-12: Bank of America Upgrades Orexigen Therapeutics from Neutral to Buy, Raises PO from \$3.5 to \$7

Financial news for OREX dated on 2012-03-08: Fresh Del Monte, BlackRock and Other Stocks Insiders Are Buying

Financial news for OREX dated on 2012-03-02: Arena Pharma Files for EMA Application, Hopes to Cure Weight Loss

Financial news for OREX dated on 2012-02-27: Orexigen Therapeutics Trading 7.2% Higher on Heavy Volume; Currently at \$4.03

Financial news for OREX dated on 2012-02-23: U.S. Obesity Spells Opportunity for VVUS, OREX and ARNA

Financial news for OREX dated on 2012-02-23: Vivus Investors Rejoice as Weight Loss Drug Receives Positive Panel Vote

Financial news for OREX dated on 2012-02-23: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2012-02-22: Orexigen Therapeutics and Arena Pharmaceuticals Soar On Positive Qnexa Panel Vote

Financial news for OREX dated on 2012-02-22: Orexigen Therapeutics, Arena Pharmaceuticals Spike Higher as FDA Panels Prepares to Vote on Vivus' Qnexa

Financial news for OREX dated on 2012-02-22: Orexigen Therapeutics Spikes to Highs

Financial news for OREX dated on 2012-02-20: Weekly Traders Homework: Contrarian Indicators Flashing (w/ Economic Calendar and Stock Radar)

Financial news for OREX dated on 2012-02-17: Vivus Hoping Weight Loss Drug Will Gain Approval as FDA Releases Briefing Documents

Financial news for OREX dated on 2012-02-12: Weekly Traders Homework: The First Sign Of Weakness In 2012

Financial news for OREX dated on 2012-02-06: Orexigen Announces Agreement From the FDA on a Special Protocol Assessment for the Contrave Outcomes Trial

Financial news for OREX dated on 2011-12-15: Orexigen Therapeutics Prices Public Offering of 5.65M Shares at \$1.45

Financial news for OREX dated on 2011-12-14: Orexigen Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Financial news for OREX dated on 2011-12-09: Arena Pharmaceuticals Spiking Higher on Heavy Volume

Financial news for OREX dated on 2011-10-21: Notable Put Options Activity in Orexigen Therapeutics

Financial news for OREX dated on 2011-10-21: Vivus Hopes FDA Approval Will Lead to Fat Profits

Financial news for OREX dated on 2011-09-22: Wednesday's NASDAQ Winners: Orexigen Therapeutics, Flamel Technologies, Mattersight, JA Solar, Holding

Financial news for OREX dated on 2011-09-21: Hearing Orexigen Therapeutics will be Mentioned on CNBC in Next Segment

Financial news for OREX dated on 2011-09-21: Hearing Orexigen Therapeutics to Appear on CNBC Shortly

Financial news for OREX dated on 2011-09-21: Option Alert: Orexigen Therapeutics October 2 Call Rises 1000%

Financial news for OREX dated on 2011-09-21: Morning Market Movers

Financial news for OREX dated on 2011-09-21: Benzinga's Top Pre-Market Gainers

Financial news for OREX dated on 2011-09-21: Hearing Lazard Downgrades Orexigen Therapeutics from Neutral to Sell with \$0.25PT

Financial news for OREX dated on 2011-09-20: UPDATE: Orexigen Therapeutics Resumes Trading

Financial news for OREX dated on 2011-09-20: Orexigen Therapeutics Resumes Trading

Financial news for OREX dated on 2011-09-20: PREVIEW: Orexigen Therapeutics to Resume Trading at 4:30pm

Financial news for OREX dated on 2011-09-20: UPDATE: Vivus and Arena Pharmaceuticals Spike Higher on Orexigen Therapeutics News

Financial news for OREX dated on 2011-09-20: Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave

Financial news for OREX dated on 2011-09-15: Orexigen Therapeutics Spiking Higher on Heavy Volume

Financial news for OREX dated on 2011-07-28: How to Profit from Exploding Government Healthcare Costs

Financial news for OREX dated on 2011-07-13: Options Brief: Orexigen Therapeutics

Financial news for OREX dated on 2011-06-06: Options Brief: Orexigen Therapeutics, Inc.

Financial news for OREX dated on 2011-06-03: Negative Rumors About Orexigen Therapeutics Circulate (OREX)

Financial news for OREX dated on 2011-06-03: Benzinga's Top Pre-Market NASDAQ Losers

Financial news for OREX dated on 2011-06-03: Orexigen's CEO Continues to Believe in the Potential of Contrave, Planning to File FDA Appeal

Financial news for OREX dated on 2011-06-03: Orexigen Therapeutics Getting Crushed As Company Puts Obesity Drug On Hold

Financial news for OREX dated on 2011-06-03: Orexigen Plunges 24% in Pre-Market After Trading Resumption, Putting on Hold Further Clinical Development

Financial news for OREX dated on 2011-06-03: Trading Resumes: Orexigen Therapeutics

Financial news for OREX dated on 2011-06-03: Orexigen Therapeutics Provides a Regulatory Update on Contrave NDA

Financial news for OREX dated on 2011-06-01: The Good, The Bad & The Ugly 06-01-2011

Financial news for OREX dated on 2011-06-01: Orexigen Therapeutics Trading Over 14% Higher Today

Financial news for OREX dated on 2011-06-01: Morning Market Movers

Financial news for OREX dated on 2011-04-28: List of Seven Cheap Biotech Stocks Expected to Grow, Seeking Alpha Reports (CHTP, TLON, HGSI, VNDA, OREX, SNTA, VICL)

Financial news for OREX dated on 2011-04-25: Benzinga's Top Pre-Market NASDAQ Losers (OREX, ZSTN, SNDK, HBAN)

Financial news for OREX dated on 2011-04-21: Market Perspective & Perception 04-21-2011

Financial news for OREX dated on 2011-04-21: Calls Purchased on Orexigen Therapeutics, Inc (OREX)

Financial news for OREX dated on 2011-04-21: Benzinga's Top Pre-Market NASDAQ Gainers (TRAD, BIIB, FFIV, OREX)

Financial news for OREX dated on 2011-04-14: Benzinga's Top Pre-Market NASDAQ Losers (INVE, OPEN, HAS, OREX)

Financial news for OREX dated on 2011-04-04: Afternoon Trade: Top and Bottom Five Percentage Gainers (MSSR, AIB, HEAT, COOL, OREX, AMIE, JGBO, HRZ, DGW, RVSN)

Financial news for OREX dated on 2011-04-04: Mid-Day Top-5 and Bottom-5 Percentage Gainers (MSSR, CRYP, COOL, OREX, AEN, AMIE, DGW, HRZ, RVSN, TPI)

Financial news for OREX dated on 2011-04-04: Orexigen And Vivus Surge On Blood Pressure Data (OREX, VVUS)

Financial news for OREX dated on 2011-04-04: Morning Trade: Top And Bottom Five Percentage Gainers (MSSR, OREX, TFCO, VVUS, CSCD, AMIE, DGW, AFFM, RVSN, IBCPO)

Financial news for OREX dated on 2011-04-04: Options Brief: Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2011-04-04: Benzinga's Top Pre-Market NASDAQ Gainers (VVUS, OREX, CIGX, TEVA)

Financial news for OREX dated on 2011-04-04: Orexigen(r) Therapeutics Presents Additional Contrave Data from Phase 3 COR-II Trial on 24-Hour Ambulatory Blood Pressure Monitoring

Financial news for OREX dated on 2011-03-10: Orexigen Therapeutics Reports Q4 EPS (\$0.24) Vs. (40.29) Estimates (OREX)

Financial news for OREX dated on 2011-02-17: Benzinga's Top Pre-Market NASDAQ Gainers (RBCN, OREX, ISPH, BRCD)

Financial news for OREX dated on 2011-02-11: Friday's Put/Call Ratio Leaders (BSBR, FLEX, CX, YRCW, OREX)

Financial news for OREX dated on 2011-02-08: Benzinga's Top Pre-Market NASDAQ Gainers (CNXT, MOTR, SNDK, OREX)

Financial news for OREX dated on 2011-02-07: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, PGNX, GOLD, GENZ)

Financial news for OREX dated on 2011-02-04: Benzinga's Top Pre-Market NASDAQ Gainers

(JDSU, AVNW, SIMG, OREX)

Financial news for OREX dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for OREX dated on 2011-02-02: Setback for Orexigen - Analyst Blog

Financial news for OREX dated on 2011-02-02: Jefferies Downgrades Orexigen Therapeutics to Hold (OREX)

Financial news for OREX dated on 2011-02-02: Benzinga's Top Downgrades (DG, OREX, DLTR, WWW)

Financial news for OREX dated on 2011-02-02: Jefferies Downgrades Orexigen Therapeutics To Hold, PT To \$2.50

Financial news for OREX dated on 2011-02-01: What's Hot on TheStreet

Financial news for OREX dated on 2011-02-01: VIVUS Trading Significantly Lower Today (VVUS)

Financial news for OREX dated on 2011-02-01: Benzinga's Top Pre-Market NASDAQ Losers (OREX, VVUS, CCME, DEPO)

Financial news for OREX dated on 2011-02-01: Trading Orexigen Therapeutics Terrible Results (OREX, ARNA, VVUS)

Financial news for OREX dated on 2011-02-01: Orexigen Therapeutics Expects to Meet with FDA This Quarter

Financial news for OREX dated on 2011-02-01: A Peek Into The Market Before The Trading Starts

Financial news for OREX dated on 2011-02-01: Trading Orexigen's FDA Rejection (VVUS, OREX)

Financial news for OREX dated on 2011-02-01: Orexigen Therapeutics Crushed After FDA Rejects Contrave Approval (OREX)

Financial news for OREX dated on 2011-02-01: FDA Concerned of Cardiovascular Safety Profile of Orexigen Therapeutics' Naltrexone

Financial news for OREX dated on 2011-01-31: SAC Capital Discloses 7.2% Stake In Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2011-01-31: Morning Market Movers (DEPO, NPSP, ZNWA, OREX)

Financial news for OREX dated on 2011-01-24: Jefferies Maintains Buy on Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2011-01-12: Low Priced Stocks to Watch today include (STKL),(GMO),(SRZ),(CGR)(OREX), yesterday saw some big winners read below.

Financial news for OREX dated on 2011-01-06: Mad Money Lightning Round OT: Cramer Is Bullish On LPX (OREX, DEER, FCX, LPX)

Financial news for OREX dated on 2011-01-06: Unconfirmed Rumors Circulate that a major Drug company will acquire Orexigen Therapeutics, Inc. (OREX) at \$17.00 a share

Financial news for OREX dated on 2010-12-30: 3 Stocks For New Year's Diets (ARNA, VVUS, OREX)

Financial news for OREX dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for OREX dated on 2010-12-27: Vivus Seeks EU Nod for Qnexa - Analyst Blog

Financial news for OREX dated on 2010-12-24: Insiders Trading AZO, MDT, FTFL

Financial news for OREX dated on 2010-12-22: Arena: Long, Hard 'Path' to Obesity Drug Approval

Financial news for OREX dated on 2010-12-15: Best Biotech CEO of 2010 Is...

Financial news for OREX dated on 2010-12-13: Unconfirmed Rumors Circulate that Takeda Pharmaceutical Co. Ltd. will acquire Orexigen Therapeutics, Inc. (OREX) in the high teens

Financial news for OREX dated on 2010-12-13: VIVUS Up Pre-Market

Financial news for OREX dated on 2010-12-13: Biotech Calendar: FDA Drug Approvals in 2011

Financial news for OREX dated on 2010-12-11: Biotech Sector Weekly Rewind

Financial news for OREX dated on 2010-12-10: Biotech Stock Mailbag: Orexigen and Vivus

Financial news for OREX dated on 2010-12-09: Orexigen Wins FDA Advisory Approval for Anti-Obesity Drug

Financial news for OREX dated on 2010-12-09: Orexigen Therapeutics CEO CNBC Appearance (OREX)

Financial news for OREX dated on 2010-12-09: Orexigen Therapeutics Dropping After Monster Gain Yesterday

Financial news for OREX dated on 2010-12-08: FDA Panel Backs OREX's Contrave - Analyst Blog

Financial news for OREX dated on 2010-12-08: Zings Of The Day

Financial news for OREX dated on 2010-12-08: FDA Panel Backs OREX's Contrave - Analyst Blog

Financial news for OREX dated on 2010-12-08: Premium Rot 12-08-2010

Financial news for OREX dated on 2010-12-08: Biotechnology Stocks Hot Off Of Orexigen Panel Vote

Financial news for OREX dated on 2010-12-08: Orexigen Therapeutics Off Highs (OREX)

Financial news for OREX dated on 2010-12-08: Top Narrow Based Indexes For December 8 (AIXG, OREX, BTN)

Financial news for OREX dated on 2010-12-08: Wednesday's Mid-Day Options Volume Leaders (C, AAPL, BAC, F, OREX)

Financial news for OREX dated on 2010-12-08: Benzinga's Volume Movers (OREX, AVAV, NXPI, GFRE)

Financial news for OREX dated on 2010-12-08: NASDAQ Stocks Hitting 52-Week Highs (FSCI, OREX, RURL, ENSG)

Financial news for OREX dated on 2010-12-08: Morning Market Movers (OREX, FCEC, VVUS, ARNA)

Financial news for OREX dated on 2010-12-08: Vivus Continues Gains Pre-Market on FDA Panel Approval (VVUS)

Financial news for OREX dated on 2010-12-08: Orexigen Up On FDA Vote

Financial news for OREX dated on 2010-12-08: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, VVUS, RYAA, AAPL)

Financial news for OREX dated on 2010-12-08: J.P. Morgan Doubles Price Target On Orexigen Therapeutics

Financial news for OREX dated on 2010-12-07: Men's Wearhouse, Orexigen: After-Hours Trading

Financial news for OREX dated on 2010-12-07: FDA Panel Approves Orexigen Diet Drug Contrave

Financial news for OREX dated on 2010-12-07: What Diet Pill Stocks To Trade Alongside Orexigen Therapeutics (OREX, ARNA, VVUS)

Financial news for OREX dated on 2010-12-07: Orexigen Therapeutics' Contrave Receives FDA Panel Approval (OREX)

Financial news for OREX dated on 2010-12-07: Vivus Skyrocketing On Vote (VVUS)

Financial news for OREX dated on 2010-12-07: Trading Halted in Orexigen Therapeutics

Financial news for OREX dated on 2010-12-07: Orexigen Therapeutics: FDA Panel Live Blog

Financial news for OREX dated on 2010-12-03: Orexigen: Predicting Tuesday's FDA Panel

Financial news for OREX dated on 2010-12-03: Benzinga's Top Pre-Market NASDAQ Losers (SMT, OREX, PWA, SPSC)

Financial news for OREX dated on 2010-12-01: Euro & Dollar are Barometers for this Rally 12-01-2010

Financial news for OREX dated on 2010-11-30: Orexigen: Contrave FDA Panel Preview

Financial news for OREX dated on 2010-11-30: Biotech Calendar: Key Dates for December

Financial news for OREX dated on 2010-11-05: Biotech Stock Mailbag: Orexigen

Financial news for OREX dated on 2010-11-03: Orexigen Therapeutics Reports Third Quarter EPS of \$(0.31)

Financial news for OREX dated on 2010-10-20: Aggressive Growth Stock Picks-Oct. 20, 2010 - Zacks Rank Buys

Financial news for OREX dated on 2010-10-20: Zacks Releases Four Powerful 'Buy' Stocks: OREX, ABV, THI, CLD - Press Releases

Financial news for OREX dated on 2010-10-20: Orexigen Therapeutics, Inc - Aggressive Growth

Financial news for OREX dated on 2010-09-17: Benzinga's Top Pre-Market NASDAQ Losers (ARNA, OREX, ACFN, VVUS)

Financial news for OREX dated on 2010-09-16: OREX: Approve Contrave, Throw Meridia Away

Financial news for OREX dated on 2010-09-02: Mid-Day Market Movers (BKC, OREX, SCMR, HWD)

Financial news for OREX dated on 2010-09-02: Benzinga's Top Pre-Market NASDAQ Gainers (OREX, CRME, MPEL, ASYS)

Financial news for OREX dated on 2010-08-09: Jefferies Has \$12 Target, Buy Rating On Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2010-07-30: Benzinga's Top Pre-Market NASDAQ Gainers (PWER, GERN, OREX, NFLX)

Financial news for OREX dated on 2010-07-16: Benzinga's Top Pre-Market NASDAQ Losers (VVUS, OREX, PLCM, MAT)

Financial news for OREX dated on 2010-07-15: Orexigen Therapeutics Plummets (OREX)

Financial news for OREX dated on 2010-07-13: Benzinga's Top Pre-Market Gainers (VVUS, OREX, ARNA, CENX)

Financial news for OREX dated on 2010-07-07: Calls Purchased on Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2010-07-06: Calls Purchased on Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2010-06-29: Benzinga's Top Pre-Market Losers (MU, OREX, ARIA, SOLF)

Financial news for OREX dated on 2010-06-28: Early Volume Plays Among Those Valued Below \$10 (BIOD, ARNA, OREX)

Financial news for OREX dated on 2010-06-28: Upside Purchased on Orexigen Therapeutics (OREX)

Financial news for OREX dated on 2010-06-28: Mid-Day Market Movers (TDBK, ONFC, PLM, DWCH)

Financial news for OREX dated on 2010-06-01: Early Volume Plays Among Those Valued Below \$10 (BEAT, OREX, ONCY, CBRX)

Financial news for OREX dated on 2010-06-01: Benzinga's Top Pre-Market Gainers (EVVV, OREX, ARMH, SHPGY, GOLD)

Financial news for OREX dated on 2010-04-12: Mike Huckman Is Watching VVUS, ARNA, OREX

Financial news for OREX dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for OREX dated on 2009-10-26: Orexigen Therapeutics (OREX) Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk

Financial news for OREX dated on 2009-08-13: Orex Exploration Inc.: Update From the Goldboro Project, Nova Scotia